Single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with fixed dose ICS (moderate certainty).
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
The review found no eligible studies for this question.
160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).
The review found no eligible studies for this question.
Intensive insulin therapy leads to higher serious adverse events, ‐ in total population randomised ‐… compared with conventional insulin therapy (high certainty).
Preloading nicotine replacement therapy (NRT) showed no clear difference in overall serious adverse events compared with standard‐use NRT (low certainty).
160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).
It is very uncertain whether summary of findings of metformin monotherapy for adults with type 2… changes serious adverse events (SAE) compared with thiazolidinediones (very low certainty).
Sublingual immunotherapy showed no clear difference in serious adverse events Weighted mean duration of studies: 56 weeks compared with control (moderate certainty).
The review found no eligible studies for this question.
Bupropion plus nicotine replacement therapy (NRT) showed no clear difference in serious adverse events compared with NRT alone (low certainty).